Extracorporeal shockwave lithotripsy and litholytic therapy in cholelithiasis.
Extracorporeal shockwave lithotripsy (ESWL) and litholytic therapy were used in 100 patients over a period of 16 months. ESWL was carried out with a Lithostar Plus and chenodeoxycholic acid was used as the lytic agent, given until 3 months after complete disappearance of stones. Within a period of 8-12 months, stones disappeared completely in 82 per cent of the patients who had a single stone less than or equal to 20 mm in diameter and in 50 per cent of those with a single stone greater than 20 mm in size or with multiple stones. Complications requiring surgery developed in five patients: three had acute cholecystitis and two developed acute pancreatitis. Of the patients in whom complete stone clearance was achieved, two of 11 followed up developed recurrence of stones 4 months after cessation of lytic therapy.
Erdamar
I
I
Department of Surgery, Dokuz Eylül University Medical School, Izmir, Turkey.
Avci
G
G
Füzün
M
M
Harmancioğlu
O
O
D000293:Adolescent; D000328:Adult; D000368:Aged; D002635:Chenodeoxycholic Acid / Q000009:adverse effects / Q000627:therapeutic use*; D002648:Child; D002769:Cholelithiasis / Q000628:therapy*; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D008096:Lithotripsy / Q000009:adverse effects; D008297:Male; D008875:Middle Aged; D012008:Recurrence; D013997:Time Factors
D002635:Chenodeoxycholic Acid